The median time to treatment failure (TTF) was 8.8 months compared with the historical duration of 6.6 months. Median progression-free survival approached 1 year, and more than 70% of patients remained alive at 1 year, according to Pascal Hammel, MD, of Hopital Beaujon in Clichy, France, and colleagues. The findings add to the combination’s activity in pancreatic cancer, following phase III results showing improved survival in association with a significant reduction in tumor burden among patients with metastatic pancreatic cancer. Read more . . .